Clinical Trial Update: Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

View source ↗

Summary

The update reports on biomarkers that may predict early failure of ibrutinib therapy in high-risk TP53-mutated chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Oncology Institute of Southern Switzerland | Conditions: Chronic Lymphocytic Leukemia | Status: COMPLETED